These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 24842961

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T.
    J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
    [Abstract] [Full Text] [Related]

  • 3. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone AM, Immovilli P, Caniatti L, Tola MR, Pesci I, Montanari E, Sola P, Granella F, Motti L, Ferraro D.
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [Abstract] [Full Text] [Related]

  • 4. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Apr; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 7. Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
    Braune S, Lang M, Bergmann A, NTC Study Group.
    J Neurol; 2013 Dec; 260(12):2981-5. PubMed ID: 24008757
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M.
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 May; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

  • 16. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N, Lahoz R, Reynolds T, Korn JR.
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [Abstract] [Full Text] [Related]

  • 17. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.